USD 66.73
(-0.75%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 1.13 Billion USD | 4.7% |
2022 | 1.08 Billion USD | 0.37% |
2021 | 1.07 Billion USD | 0.37% |
2020 | 1.07 Billion USD | 26.77% |
2019 | 848.12 Million USD | 2.13% |
2018 | 830.41 Million USD | -29.29% |
2017 | 1.17 Billion USD | 71.9% |
2016 | 683.23 Million USD | 3.16% |
2015 | 662.28 Million USD | 0.66% |
2014 | 657.97 Million USD | 0.37% |
2013 | 655.56 Million USD | 88.26% |
2012 | 348.22 Million USD | -0.03% |
2011 | 348.32 Million USD | -7.73% |
2010 | 377.52 Million USD | -24.05% |
2009 | 497.08 Million USD | 602.68% |
2008 | 70.74 Million USD | -85.96% |
2007 | 503.68 Million USD | 118.3% |
2006 | 230.72 Million USD | 2.88% |
2005 | 224.25 Million USD | -17.2% |
2004 | 270.84 Million USD | 116.67% |
2003 | 125 Million USD | 1443.21% |
2002 | 8.1 Million USD | 45.89% |
2001 | 5.55 Million USD | 6589.16% |
2000 | 83 Thousand USD | -25.23% |
1999 | 111 Thousand USD | 11.0% |
1998 | 100 Thousand USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 1.08 Billion USD | 0.09% |
2024 Q2 | 1.09 Billion USD | 1.07% |
2024 Q3 | 594.62 Billion USD | -45.19% |
2023 Q3 | 1.08 Billion USD | 0.09% |
2023 FY | 1.13 Billion USD | 4.7% |
2023 Q4 | 1.08 Billion USD | 0.09% |
2023 Q1 | 1.08 Billion USD | 0.09% |
2023 Q2 | 1.08 Billion USD | 0.09% |
2022 Q4 | 1.08 Billion USD | 0.09% |
2022 Q3 | 1.08 Billion USD | 0.09% |
2022 FY | 1.08 Billion USD | 0.37% |
2022 Q1 | 1.09 Billion USD | 1.09% |
2022 Q2 | 1.08 Billion USD | -0.9% |
2021 Q3 | 1.07 Billion USD | 0.09% |
2021 Q4 | 1.07 Billion USD | 0.09% |
2021 FY | 1.07 Billion USD | 0.37% |
2021 Q1 | 1.07 Billion USD | 0.09% |
2021 Q2 | 1.07 Billion USD | 0.09% |
2020 FY | 1.07 Billion USD | 26.77% |
2020 Q3 | 1.44 Billion USD | 0.36% |
2020 Q1 | 852.67 Million USD | 0.54% |
2020 Q2 | 1.44 Billion USD | 69.27% |
2020 Q4 | 1.07 Billion USD | -25.77% |
2019 Q3 | 843.61 Million USD | 0.53% |
2019 FY | 848.12 Million USD | 2.13% |
2019 Q1 | 834.76 Million USD | 0.52% |
2019 Q2 | 839.16 Million USD | 0.53% |
2019 Q4 | 848.12 Million USD | 0.53% |
2018 Q1 | 1.18 Billion USD | 0.73% |
2018 FY | 830.41 Million USD | -29.29% |
2018 Q4 | 830.41 Million USD | -30.82% |
2018 Q3 | 1.2 Billion USD | 0.73% |
2018 Q2 | 1.19 Billion USD | 0.73% |
2017 Q3 | 1.16 Billion USD | 72.44% |
2017 Q1 | 690.93 Million USD | 1.13% |
2017 FY | 1.17 Billion USD | 71.9% |
2017 Q2 | 676.2 Million USD | -2.13% |
2017 Q4 | 1.17 Billion USD | 0.72% |
2016 Q1 | 668 Million USD | 0.86% |
2016 Q4 | 683.23 Million USD | 1.13% |
2016 FY | 683.23 Million USD | 3.16% |
2016 Q3 | 675.63 Million USD | 0.83% |
2016 Q2 | 670.1 Million USD | 0.31% |
2015 Q1 | 655.49 Million USD | -0.38% |
2015 Q2 | 661.49 Million USD | 0.92% |
2015 Q4 | 662.28 Million USD | -0.82% |
2015 FY | 662.28 Million USD | 0.66% |
2015 Q3 | 667.79 Million USD | 0.95% |
2014 Q2 | 650.87 Million USD | -1.59% |
2014 FY | 657.97 Million USD | 0.37% |
2014 Q3 | 656.88 Million USD | 0.92% |
2014 Q4 | 657.97 Million USD | 0.17% |
2014 Q1 | 661.41 Million USD | 0.89% |
2013 Q3 | 78.31 Million USD | -28.69% |
2013 Q1 | 109.84 Million USD | -68.45% |
2013 Q2 | 109.82 Million USD | -0.02% |
2013 FY | 655.56 Million USD | 88.26% |
2013 Q4 | 655.56 Million USD | 737.14% |
2012 FY | 348.22 Million USD | -0.03% |
2012 Q4 | 348.22 Million USD | -0.02% |
2012 Q1 | 348.32 Million USD | -0.0% |
2012 Q2 | 348.3 Million USD | -0.01% |
2012 Q3 | 348.3 Million USD | -0.0% |
2011 Q4 | 348.32 Million USD | -0.0% |
2011 FY | 348.32 Million USD | -7.73% |
2011 Q3 | 348.33 Million USD | -7.73% |
2011 Q1 | 377.52 Million USD | 0.0% |
2011 Q2 | 377.52 Million USD | -0.0% |
2010 Q3 | 497.08 Million USD | 0.0% |
2010 FY | 377.52 Million USD | -24.05% |
2010 Q2 | 497.08 Million USD | 0.0% |
2010 Q1 | 497.08 Million USD | 0.0% |
2010 Q4 | 377.52 Million USD | -24.05% |
2009 Q4 | 497.08 Million USD | 0.0% |
2009 FY | 497.08 Million USD | 602.68% |
2009 Q1 | 567.4 Million USD | -0.07% |
2009 Q2 | 497.08 Million USD | -12.39% |
2009 Q3 | 497.08 Million USD | 0.0% |
2008 Q4 | 567.82 Million USD | 14.2% |
2008 Q3 | 497.24 Million USD | -1.16% |
2008 Q1 | 503.36 Million USD | -0.06% |
2008 Q2 | 503.06 Million USD | -0.06% |
2008 FY | 70.74 Million USD | -85.96% |
2007 FY | 503.68 Million USD | 118.3% |
2007 Q1 | 247.23 Million USD | 7.15% |
2007 Q2 | 571.49 Million USD | 131.16% |
2007 Q3 | 570.87 Million USD | -0.11% |
2007 Q4 | 503.68 Million USD | -11.77% |
2006 Q2 | 374.01 Million USD | -5.28% |
2006 Q3 | 299.87 Million USD | -19.82% |
2006 Q1 | 394.88 Million USD | 76.08% |
2006 FY | 230.72 Million USD | 2.88% |
2006 Q4 | 230.72 Million USD | -23.06% |
2005 FY | 224.25 Million USD | -17.2% |
2005 Q3 | 226.14 Million USD | -0.86% |
2005 Q2 | 228.11 Million USD | 34.45% |
2005 Q1 | 169.65 Million USD | -37.36% |
2005 Q4 | 224.25 Million USD | -0.83% |
2004 FY | 270.84 Million USD | 116.67% |
2004 Q1 | 125 Million USD | 0.0% |
2004 Q2 | 187 Million USD | 49.6% |
2004 Q3 | 270.8 Million USD | 44.81% |
2004 Q4 | 270.84 Million USD | 0.01% |
2003 Q4 | 125 Million USD | 0.0% |
2003 Q3 | 125 Million USD | 0.0% |
2003 Q2 | 125 Million USD | 2677.78% |
2003 Q1 | 4.5 Million USD | -13.46% |
2003 FY | 125 Million USD | 1443.21% |
2002 Q1 | 5.22 Million USD | -5.96% |
2002 FY | 8.1 Million USD | 45.89% |
2002 Q4 | 5.2 Million USD | 78.57% |
2002 Q2 | 3.5 Million USD | -32.96% |
2002 Q3 | 2.91 Million USD | -16.8% |
2001 Q4 | 5.55 Million USD | 2203.73% |
2001 Q2 | 296 Thousand USD | 289.47% |
2001 Q1 | 76 Thousand USD | -8.43% |
2001 Q3 | 241 Thousand USD | -18.58% |
2001 FY | 5.55 Million USD | 6589.16% |
2000 Q2 | 97 Thousand USD | -5.83% |
2000 Q3 | 91 Thousand USD | -6.19% |
2000 FY | 83 Thousand USD | -25.23% |
2000 Q1 | 103 Thousand USD | -7.21% |
2000 Q4 | 83 Thousand USD | -8.79% |
1999 Q3 | 100 Thousand USD | -99.62% |
1999 Q2 | 26.1 Million USD | 26000.0% |
1999 Q1 | 100 Thousand USD | 0.0% |
1999 FY | 111 Thousand USD | 11.0% |
1999 Q4 | 111 Thousand USD | 11.0% |
1998 FY | 100 Thousand USD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Editas Medicine, Inc. | 36.53 Million USD | -3003.446% |
Dynavax Technologies Corporation | 256.91 Million USD | -341.344% |
Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -2630.452% |
Perrigo Company plc | 4.07 Billion USD | 72.164% |
Illumina, Inc. | 2.26 Billion USD | 49.873% |
Thermo Fisher Scientific Inc. | 34.91 Billion USD | 96.753% |
Iovance Biotherapeutics, Inc. | 1 Million USD | -113287.5% |
Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 88.132% |
IQVIA Holdings Inc. | 14.23 Billion USD | 92.032% |
Heron Therapeutics, Inc. | 173.75 Million USD | -552.579% |
Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 58.05% |
Unity Biotechnology, Inc. | 26.99 Million USD | -4101.093% |
Waters Corporation | 2.35 Billion USD | 51.863% |
Biogen Inc. | 7.33 Billion USD | 84.548% |
Sangamo Therapeutics, Inc. | 38.1 Million USD | -2875.737% |
Evolus, Inc. | 126.54 Million USD | -796.018% |
Adicet Bio, Inc. | 17.7 Million USD | -6304.988% |
Cara Therapeutics, Inc. | 43.16 Million USD | -2526.717% |
bluebird bio, Inc. | 330.32 Million USD | -243.259% |
Esperion Therapeutics, Inc. | 540.94 Million USD | -109.609% |
FibroGen, Inc. | 170.45 Million USD | -565.205% |
Agilent Technologies, Inc. | 2.73 Billion USD | 58.542% |
Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -5329.335% |
Homology Medicines, Inc. | 44.05 Million USD | -2473.83% |
Geron Corporation | 85.89 Million USD | -1220.01% |
Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 52.716% |
Amicus Therapeutics, Inc. | 445.05 Million USD | -154.77% |
Myriad Genetics, Inc. | 145 Million USD | -681.983% |
Viking Therapeutics, Inc. | 1.26 Million USD | -89890.079% |
Intellia Therapeutics, Inc. | 115.34 Million USD | -883.021% |
Zoetis Inc. | 6.8 Billion USD | 83.333% |
Abeona Therapeutics Inc. | 4.4 Million USD | -25658.178% |
Mettler-Toledo International Inc. | 2.16 Billion USD | 47.694% |
Vertex Pharmaceuticals Incorporated | 808.4 Million USD | -40.262% |
Kala Pharmaceuticals, Inc. | 36.32 Million USD | -3021.645% |
Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 21.992% |
Atara Biotherapeutics, Inc. | 57.87 Million USD | -1859.281% |
Verastem, Inc. | 41.55 Million USD | -2628.481% |
Nektar Therapeutics | 230.4 Million USD | -392.131% |
Axsome Therapeutics, Inc. | 186.37 Million USD | -508.393% |
Aclaris Therapeutics, Inc. | 3.07 Million USD | -36785.979% |
Sarepta Therapeutics, Inc. | 1.39 Billion USD | 18.824% |
OPKO Health, Inc. | 326.56 Million USD | -247.214% |
Exelixis, Inc. | 189.94 Million USD | -496.952% |
Neurocrine Biosciences, Inc. | 428.4 Million USD | -164.677% |
Corcept Therapeutics Incorporated | 151 Thousand USD | -750810.596% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
uniQure N.V. | 138.4 Million USD | -719.221% |
Imunon, Inc. | 1.13 Million USD | -99424.442% |
Blueprint Medicines Corporation | 774.12 Million USD | -46.472% |
Insmed Incorporated | 1.2 Billion USD | 5.824% |
Halozyme Therapeutics, Inc. | 1.49 Billion USD | 24.37% |
Agios Pharmaceuticals, Inc. | 56.98 Million USD | -1889.673% |
TG Therapeutics, Inc. | 110.79 Million USD | -923.399% |
Incyte Corporation | 38.28 Million USD | -2861.514% |
Emergent BioSolutions Inc. | 877.5 Million USD | -29.217% |